Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Approved
Current status date:
2020-08-13
Product name:
CABAZITAXEL FOR INJECTION
Description:
SINGE USE VIAL WITH DILUENT
DIN:
02503581
Product Monograph/Veterinary Labelling:
Date:
2020-08-11
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
MARCAN PHARMACEUTICALS INC
2 Gurdwara Rd., Suite 112
Ottawa
Ontario
Canada
K2E 1A2
Class:
Human
Dosage form(s):
Solution , Kit
Route(s) of administration:
Intravenous
Number of active ingredient(s):
1
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
10:00.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
L01CD04 CABAZITAXEL
Active ingredient group (AIG) number:See footnote5
0152936001
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| CABAZITAXEL | 40 MG / ML |